Contrasting natures of lung growth after transplantation and lobectomy  by Kaza, Aditya K. et al.
288 The Journal of Thoracic and Cardiovascular Surgery • February 2002
General Thoracic Surgery Kaza et al
ED
ITO
RIA
L
CH
D
G
TS
G
TS
ET
CSP
TX
Objective: We hypothesized that posttransplantation lung growth in an immature
recipient and postlobectomy compensatory lung growth are two distinct processes.
Methods: Mature swine underwent left upper lobectomy, and growth of the left
lower lobe was studied after 2 weeks and after 3 months. Left lower lobes from
another set of mature pigs were transplanted into immature animals, and growth of
the transplanted lobe was then studied after 2 weeks and after 3 months. Left lower
lobes from mature animals that did not undergo operation were used as normal con-
trol lobes. The lobes were weighed on removal and fixed intrabronchially. Sections
stained with hematoxylin and eosin were used to determine alveolar surface density
and percentage volume of respiratory region. Immunostaining for 5-bromo-2´-
deoxyuridine was used to determine alveolar cell proliferation index, and epidermal
growth factor receptor expression was detected by Western blot.
Results: Postlobectomy lung growth (increase in lobe weight) reached statistical sig-
nificance at 2 weeks, with a concomitant rise in cell proliferation index. The trans-
planted lobe, in contrast, exhibited a gradual growth response, with a statistically
significant increase in cell proliferation index at 3 months. Volume of respiratory
region was noted to increase only in the transplanted lobe at 3 months. Epidermal
growth factor receptor expression was upwardly regulated relative to that in normal
control lobes in the 2-week postlobectomy and 3-month posttransplantation lobes.
Conclusions: Postlobectomy lung growth appears to be regulated by a different
mechanism than is posttransplantation lung growth and is a more rapid and restora-
tive process. The growth peaks in both processes correlate with upward regulation
of cell proliferation index and epidermal growth factor receptor expression.
Treatment of various pulmonary conditions, such as congenital lungdisorders, end-stage lung disease, and lung injury, could directly ben-efit from a better understanding of lung growth. The definitive treat-ment for end-stage lung disease continues to be lung transplantation.Lung disease, both congenital and acquired, has been noted to be onthe rise. This poses a unique problem for the scientific community.
Lung allografts for transplantation remain scarce. Understanding the various mech-
anisms and aspects of lung growth thus has potential applications in the clinical
realm. The lung transplant organ shortage has severely hindered the treatment of
patients with end-stage lung disease. This problem was partially relieved by the use
of reduced-size allografts, which has resulted in many patients being treated, allow-
ing the use of donor lungs for maximal benefit.1 However, the issue of lung growth
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after transplantation remains a real problem that requires a
better understanding of the various underlying mechanisms.
Our laboratory has been successful in showing that adult
lungs do exhibit growth when transplanted into an immature
recipient.2,3 We believe that this growth response is related
to the various circulating humoral factors that are present in
the immature recipient. In this study we sought to compare
two distinct mechanisms of lung growth. First, both experi-
mental and human studies have shown the growth of the
remaining lung after removal of a part of it (lobectomy),
classically termed compensatory growth.4-7 Second, our lab-
oratory and other groups have demonstrated the growth of
the transplanted lung in the experimental setting.2,3,8 The
goal of this study was to compare the lung growth observed
in these two distinct processes. This understanding will help
to formulate better mechanisms for the clinical modulation
of lung growth.
Material and Methods
Experimental Groups
We used a porcine model of reduced-size lung transplantation with
animals matched at the major histocompatibility complex to
reduce the effects of chronic rejection.9 As a result of rapid post-
natal development in swine, the lungs of animals 5 months of age
or older are considered fully mature and no longer undergoing
growth in the normal host.10 Mature Hanford miniature swine at
least 5 months of age underwent left lower lobe (LLL) removal for
implantation into an immature recipient. Immature recipient ani-
mals were less than 8 weeks of age. A second group of mature ani-
mals (age >5 months) underwent left upper lobectomy to study
compensatory LLL growth in the mature host. A third group of
mature swine that had not been operated on underwent removal of
LLL tissue to serve as normal control lobes. Lung tissue from con-
trol animals was analyzed for cellular and molecular features of
growth and subsequently compared with posttransplantation and
postlobectomy tissues at 2 weeks and 3 months after the operation.
Each group at each time point was composed of 5 animals.
Left Upper Lobectomy Procedure
Swine were anesthetized with an intramuscular tiletamine and
zolazepam (Telazol) and xylazine mixture. The animals underwent
endotracheal intubation and continuous anesthesia with 1% to 2%
inhalational halothane. A left posterolateral thoracotomy was per-
formed, and the hemiazygous vein was divided to enhance expo-
sure of the left hilum. The inferior pulmonary ligament was
divided to the level of the inferior pulmonary vein. After the intra-
venous administration of heparin sodium (200 U/kg), the pul-
monary venous and arterial branches to the left upper lobe were
individually ligated and divided. The bronchus to the left upper
lobe was then ligated and divided, with care not to encroach upon
the LLL bronchus. Finally, the fissure between the left upper and
lower lobes was sharply divided to complete the left upper lobec-
tomy in this group. A chest tube was placed to underwater suction
drainage, and the chest was closed in layers. At the completion of
the procedure 0.25% bupivacaine hydrochloride (Sensorcaine)
was used for an intercostal nerve block.
For the LLL harvest procedure, immediately on completion of
a left upper lobectomy as described previously, 30 µg
prostaglandin E1 was infused into the left pulmonary artery. The
main pulmonary artery was then clamped, and a 16-gauge angio-
catheter was inserted distally with its tip directed into the left pul-
monary artery. After venting of the heart through a left atriotomy,
1 L Euro-Collins preservation solution at 4°C was infused from a
height of 30 cm. Room air ventilation was continued throughout
the flush period. Topical cooling of the LLL was achieved with
cold saline slush. The LLL was then rapidly excised and prepared
on the back table for implantation.
Recipient Left Pneumonectomy and LLL Implantation
The techniques of recipient pneumonectomy and LLL implanta-
tion have been previously described elsewhere by our laboratory.2
With the animal under 1% to 2% inhalational halothane anesthe-
sia, a posterolateral thoracotomy was performed. After the intra-
venous administration of heparin sodium (200 U/kg), the left lung
was removed.
After preparation and weighing of the mature donor LLL, the
implantation procedure began. The bronchial anastomosis was
performed first with a continuous 4-0 polypropylene suture. To
compensate for the size disparity between the large donor LLL
bronchus and the smaller recipient left main stem bronchus, the
latter was telescoped into the former for a distance of approxi-
mately 0.5 cm. To test for air leaks, the completed airway anasto-
mosis was immersed in saline solution while the LLL was
ventilated at high pressures. The pulmonary arterial anastomosis
was then performed with a continuous 5-0 polypropylene suture.
Finally, the donor left atrial cuff was anastomosed to the recipient
left atrial appendage with a continuous 5-0 polypropylene suture.
Tube thoracostomy, intercostal nerve block, and chest closure
were all performed in the same manner as described previously.
Although chest closure was challenging in all transplant recipients
because of marked size disparities between the voluminous donor
lobes and the small recipient left hemithoraces, pneumoreduction
procedures did not prove necessary.
All animals received humane care in accordance with the
“Guide for the Care and Use of Laboratory Animals” prepared by
the Institute of Laboratory Animal Resources, National Research
Council, and published by the National Academy Press, revised
1996. The protocol described here was approved by the animal
review committee of the University of Virginia.
Removal for Study of LLL Tissue
Animals in the transplantation, lobectomy, and normal control
groups received intravenous injections of 5-bromo-2´-deoxyuridine
(BrdU, 50 mg/kg; Sigma, St Louis, Mo) 16 hours before the time
designated for LLL excision. This agent facilitated the later identifi-
cation of proliferating cells by the technique described here (BrdU
immunohistochemical staining). Animals were then anesthetized
with intravenously administered sodium pentobarbital and weighed
while undergoing room air endotracheal ventilation. Through a left
posterolateral thoracotomy, the LLL was dissected free of adhesions
within the left hemithorax. After lethal injection of sodium pento-
barbital and exsanguination through a left atriotomy, the LLL was
rapidly excised and weighed. A small peripheral portion of the LLL
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was clamped, and a sample of fresh lung tissue was excised and
frozen for subsequent determination of wet to dry weight ratios and
molecular analyses. The remainder of the lung tissue was fixed
through intrabronchial instillation of 70% ethanol from a height of
25 cm. At the completion of the fixation process, the bronchus was
clamped and the lobe was stored inflated at 4°C in 70% ethanol for
24 hours. Fixed tissue was then embedded in paraffin and used for
morphometric and cell proliferation analyses.
Morphometric Analysis
Approximately 10 peripheral tissue blocks (1 cm3 each) were pre-
pared by random sampling of fixed lung tissue. Tissue blocks were
embedded in paraffin, and 5-µm sections were stained with hema-
toxylin and eosin. Morphometric analysis was then performed in a
manner similar to that of Davies11 and Wandel and colleagues.12
Each tissue section was examined under a Nikon Eclipse E400
microscope (Nikon Inc, Melville, NY) equipped with an eyepiece
reticule containing a 42-point test lattice with 85-µm grid line
lengths. By systematically selecting every third microscopic field,
at least 4 fields were analyzed for each section. The first analysis
was performed under 40 times magnification and consisted of
counting all points falling on intra-acinar air spaces or intervening
alveolar walls or septa (Pr). The percentage volume of respiratory
region (Vvr) was then calculated from the equation Vvr = (Pr/Pp)
× 100%, where Pp was the total number of test points per field
(42). Because Vvr includes the volume density of alveolar air
spaces, duct spaces, and septal tissue, this parameter represents
the percentage of peripheral lung composed of gas-exchanging
parenchyma. It therefore excludes nonparenchymal tissues such as
conducting airways and vasculature.
At 200 times magnification the number of grid lines intercept-
ing the airspace-epithelial interface (Is) was counted. From this
value the alveolar surface density (Sv) could be calculated as Sv =
(2/d) × (Is/Pp), where d was the length of each test grid line (85
µm) and Sv represents the alveolar surface area in square centime-
ters per cubic centimeter of peripheral lung.
BrdU Immunohistochemical Study
BrdU is a thymidine analog that is incorporated into replicating
DNA during the S phase of the cell cycle. This molecule has been
adopted as a marker for cellular proliferation13 and has become a
valuable research tool for studies of pneumocyte proliferation and
lung growth. Peripheral lung sections were incubated with anti-
BrdU monoclonal antibody (1:100; DAKO Corporation,
Carpinteria, Calif). Immunohistochemical detection of BrdU-
labeled nuclei was facilitated by the alkaline phosphatase system
(VectaStain ABC-AP kit; Vector Laboratories, Inc, Burlingame,
Calif). A nuclear fast red counterstain was used to discern non-
replicating nuclei. Examining the tissue sections under light
microscopy, both BrdU-labeled and unlabeled nuclei were counted
in a systematic fashion. For each animal at least 500 nuclei were
counted from cells comprising the gas-exchange compartment
(alveolar wall cells lining the alveolar airspaces). Nuclei in the
immediate vicinity of conducting airways and vasculature were
excluded from the analysis. Results were expressed as the alveolar
cell proliferation index (CPI), defined as the percentage of nuclei
labeled with BrdU.
Western Blot Analysis of Epidermal Growth Factor
Receptor
Peripheral lung samples (0.25 g) were homogenized in 50-mmol/L
tris(hydroxymethyl)aminomethane (Tris) hydrochloride, pH 7.4, 0.1-
mmol/L ethylenediaminetetraacetic acid, 0.1-mmol/L ethylenegly-
col-bis-(β-aminoethylether)-N,N,N´,N´-tetraacetic acid, 1-mmol/L
phenylmethylsulfonyl fluoride, 4-µg/mL pepstatin A, 4-µg/mL
leupeptin, and 0.1% 2-mercaptoethanol and were centrifuged at
4°C at 5000 rpm. Protein concentrations were determined with
Coomassie Plus Protein Assay Reagent (Pierce Chemical
Company, Rockford, Ill). Purified lung protein (125 µg) was frac-
tionated on a denaturing 7.5% polyacrylamide gel and subse-
quently transferred to nitrocellulose. The blot was incubated with
primary antibody to epidermal growth factor receptor (EGFR, 1
µg/mL; Santa Cruz Biotechnology, Inc, Santa Cruz, Calif) for 2
hours at room temperature. This was then washed with 50-mmol/L
Tris hydrochloride, pH 7.4, 150-mmol/L sodium chloride, and
0.1% 20-polysorbate and was incubated for 1 hour with secondary
antibody coupled to horseradish peroxidase.
After a second washing, protein bands were identified by
chemiluminescence (ECL; Amersham Pharmacia Biotech, Inc,
Piscataway, NJ) and quantitated by computerized densitometry
(Alpha Imager 2000; Alpha Innotech Corporation, San Leandro,
Calif). The units for quantitation of bands on Western blot are rel-
ative density units, not absolute numbers, and thus one cannot
directly compare data from separate figures. EGFR protein was
confirmed by its known molecular weight of 170 kd14 and also by
Western blot analysis of EGFR expression in A431 human carci-
noma cells (not shown).
Statistical Analysis
Analysis of variance and the Bonferroni multiple comparison test
were used to determine statistically significant differences among
the three groups. When only two values were compared, a paired
samples test was employed. Measurements are reported as mean ±
SEM.
Figure 1. Mean LLL weights among lobectomy (closed squares),
transplantation (closed diamonds), and normal control (Norm)
groups at 2-week and 3-month intervals. Asterisk indicates P <
.001 relative to normal control group; pound sign indicates P < .001
relative to transplantation group at 2 weeks. Error bars represent
SEM.
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Results
LLL Weights
The LLL weights in control, transplantation, and lobectomy
groups were compared. The lobectomy group exhibited a
statistically significant increase in lobar weight at 2 weeks
that was sustained at 3 months (Figure 1). The transplanted
lobes exhibited an increase in weight at 3 months that
approached a statistically significant difference from nor-
mal control lobes (Figure 1). In addition, lobe weight in the
lobectomy group was statistically significantly greater than
that in the transplantation group at 2 postsurgical weeks.
This represents the rapid nature of postlobectomy compen-
satory lung growth. The reduced-size lung transplants also
exhibited growth; however, this response appeared to be
slower than the compensatory lung growth.
Total body weight increased by 139% in the transplanta-
tion group after 3 months (from 9.7 ± 0.4 kg to 23.2 ± 1.9
kg). The 48% increase in transplanted lobe weight in the
transplantation group (from 92.8 ± 5.1 g to 137.8 ± 6.7 g)
was not in proportion to body weight, however, probably
because of to the initial large size of the implanted adult
lobe, which filled the hemithoracic cavity.
Alveolar CPI
The alveolar CPI was determined with BrdU immunostain-
ing. The lobectomy group exhibited a statistically signifi-
cant increase in alveolar CPI at 2 weeks, with a return to
baseline levels by 3 months (Figure 2). In contrast, the
transplanted lobe exhibited a slower increase in CPI, reach-
ing a statistically significant increase relative to normal con-
trol and lobectomy groups at 3 months (Figure 2).
Morphometric Analysis
Analysis of the Vvr revealed that the transplanted lobe
exhibited a statistically significant increase in Vvr at 3
months relative to the other groups (Figure 3). Sv, which
represents the alveolar surface area in square centimeters
per cubic centimeter of lung parenchyma, was not signifi-
cantly changed by both lobectomy and posttransplantation
lung growth (Figure 3).
EGFR Expression
Western blot analysis revealed that the lobectomy group had
a statistically significant upward regulation of EGFR
expression at 2 weeks relative to the normal control group;
this was noted to return to baseline levels at 3 months
(Figure 4). Comparison of EGFR expression between the
lobectomy and transplantation groups at 3 months revealed
that the transplantation group had upward regulation rela-
tive to both the lobectomy and normal control groups
Figure 2. Mean alveolar CPI among lobectomy (closed squares),
transplantation (closed diamonds), and normal control (Norm)
groups at 2-week and 3-month intervals. Asterisk indicates P <
.001 relative to normal control group; pound sign indicates P < .001
relative to transplantation group at 2 weeks; at sign indicates P <
.001 relative to lobectomy group at 3 months. Error bars represent
SEM.
Figure 3. Morphometric parameters (A, Vvr; B, Sv) among lobec-
tomy (closed squares), transplantation (closed diamonds), and
normal control (Norm) groups at 2-week and 3-month intervals.
Asterisk indicates P < .001 relative to normal control group and to
lobectomy group at 3 months. Error bars represent SEM.
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(Figure 5). In both Figures 4 and 5, EGFR expression at 3
months was slightly lower than in normal control lobes, but
not statistically significantly, and any apparent differences
are assumed to be due to slight variations in results between
the different Western blot experiments.
Discussion
An understanding of the various mechanisms and aspects of
lung growth has important applications in the clinical
realm. The lung transplant organ shortage has severely hin-
dered the treatment of patients with end-stage lung disease.
The issue of lung growth after transplantation remains a real
problem that requires a better understanding of the various
underlying mechanisms. The goal of this study was to com-
pare the nature of lung growth in two distinct processes,
posttransplantation lung growth and postlobectomy com-
pensatory lung growth. These findings will help us to
understand these two different processes of lung growth and
thus help to formulate therapies for their modulation.
In our experiments compensatory lung growth after
lobectomy was seen as a rapid process that reached statisti-
cal significance at 2 weeks, as illustrated by the gain in
lobar weight. This growth was sustained at the 3-month
interval. Posttransplantation lung growth, on the other hand,
was seen as a gradual process that approached statistical
significance at 3 months. To determine whether this
increase in lobar weight was true growth, wet to dry ratios
were determined to rule out edema as a cause of the
increased weight. These ratios were similar among all
groups (5.6 ± 0.1, 5.6 ± 0.3, and 5.9 ± 0.5 for normal con-
trol, transplantation, and lobectomy groups, respectively,
difference not statistically significant); we thus can con-
clude that this gain in lobar weight was indeed tissue
growth and that edema was not a contributing factor. We
can postulate various reasons for the differences in growth
during each of these processes. Free space in the thorax
after lobectomy could explain the more rapid growth in the
compensatory growth process, and possible ischemia-reper-
fusion injury in the transplantation group could serve as a
stimulus for cytokine and growth factor production, which
could be an additional method of growth stimulation.
We terminated our study at the 3-month time point
because this was a long enough period to observe long-term
growth while preventing unnecessary costs of prolonged
animal housing. In addition, we wanted the study to be con-
sistent with our previous studies, which also used the 3-
month postsurgical growth period. We predict that
continued lung growth would be observed on longer follow-
up times, at least in the transplantation group. We did not
conduct any lung function analysis in this study; however,
previous studies by our laboratory have demonstrated that
mature lobar transplantation, when compared to lobectomy,
resulted in no statistically significant differences in func-
Figure 4. EGFR expression in lobectomy group at 2-week (L2) and
3-month (L3) intervals compared with that in normal control group
(Norm). A, Representative Western blot. B, Relative densitometry
quantitation. Asterisk indicates P < .002 relative to normal control
group and to lobectomy group at 3 months.
Figure 5. EGFR expression at 3-month time interval in lobectomy
(L3), transplant (T3), and normal control (Norm) groups. A,
Representative Western blot. B, Relative densitometry quantita-
tion. Asterisk indicates P < .002 relative to normal control group
and to lobectomy group at 3 months.
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tional residual capacity, wet to dry weight ratios, or oxy-
genation.2,3
The next thing we wanted to examine was the mitogenic
response in the lung during each of these growth processes.
We measured this property with BrdU immunostaining
techniques for proliferating alveolar cells in the lung.
Compensatory lung growth exhibited a statistically signifi-
cant increase in CPI at the 2-week interval, with a return to
baseline levels at 3 months. Posttransplantation lung growth
on the other hand, exhibited a gradual increase in CPI,
reaching statistical significance at 3 months. This further
indicates that compensatory lung growth is a rapid process,
whereas posttransplantation lung growth represents a more
gradual process. Once again, it is important to realize the
constraints on posttransplantation lung growth in our
model, including the issue of free space in the thorax. The
transplanted lungs fit snugly in the left hemithoracic space,
and this may have hindered rapid growth of these lungs.
Morphometric techniques were used to calculate Vvr,
which represents the percentage of peripheral lung that is
occupied by alveoli and interalveolar tissue. Only the trans-
planted lobe exhibited an increase in Vvr at 3 months. It is
important to realize that even though the compensatory
growth process did not appear to increase Vvr, we can con-
clude that the overall compartment in the lung did increase
because the total amount of lobar tissue (as measured by
weight) increased statistically significantly. Another mor-
phometric parameter that we measured was alveolar surface
density (Sv), which represents the alveolar surface area per
unit volume of peripheral lung tissue. This parameter was
constant in both postlobectomy and posttransplantation lung
growth. The microscopic architecture of the alveoli was pre-
served in both these growth processes regardless of the time
interval, and the alveoli in neither process exhibited hyper-
inflation or distension. Once again because of the increase in
lobar tissue, we can infer that the total number of alveoli
increased in the compensatory growth process at 2 weeks
and in the posttransplantation growth process at 3 months.
Measurement of Vvr and Sv is not a simple technique,
and interpretation of morphometric data can be even more
perplexing. Sv is an indicator of the complexity of alveolar
structure. Because we observed normal lung architecture in
all the groups, any changes in Sv were most likely due to
changes in alveolar size (decreased alveolar size would lead
to increased Sv and vice versa). As indicated in Figure 3, we
found no statistically significant differences in Sv among
any of the groups, but we did find a statistically significant
increase in Vvr in the transplantation group. By evaluating
the lobe weight, Sv, and Vvr data together in the transplan-
tation group, the increase in Vvr with constant Sv indicates
that the increase in lung tissue (weight) most likely
occurred through increase in the number of alveoli, espe-
cially because normal lung architecture was maintained.
The relationship between Vvr and Sv is difficult to ascer-
tain. Rapid growth of the lung resulting in increased Vvr
could be explained by decreased alveolar size (decreased
Sv) and could indicate that the new alveoli were growing by
budding or sprouting from existing alveolar sacs. However,
the mechanisms of alveolar growth after lobectomy and
transplantation are not known. The morphometric measure-
ments that we conducted do not allow us to determine the
method of alveolar growth or structure, and further studies
will be necessary to determine this. Increased Vvr could
also occur by alveolar hypertrophy. In addition, we looked
at only two time points (2 weeks and 3 months), and it is
possible that peak periods of rapid alveolar growth occurred
at a time point that was not evaluated in our study.
Unfortunately, the expense of the pig transplantation model
precludes us from testing many time points.
Circulating growth factors are important stimuli for
growth. We focused on EGFR expression because epider-
mal growth factor (EGF) has been shown to play an impor-
tant role in pulmonary morphogenesis and type II
pneumocyte proliferation.15,16 Comparing the normal con-
trol group with the lobectomy group, we observed an
upward regulation of EGFR at 2 weeks after lobectomy,
which returned to baseline at 3 months. Next we compared
how the lobectomy and transplantation groups compared
with the normal control group at 3 months. We observed
that the transplanted lobes exhibited an upward regulation
of EGFR at 3 months when compared with the lobectomy
and normal control groups. The upward regulation of EGFR
in both models coincided with the time that statistically sig-
nificant growth was apparent in terms of increased CPI.
Although we have not shown any causal relationship
between EGF and lung growth, we did show in another
study that the administration of EGF stimulates post-pneu-
monectomy lung growth.17 In that study we noted that EGF
administration correlated with upward regulation of EGFR.
This association between lung growth and EGFR upward
regulation in both posttransplantation and compensatory
growth processes could represent a novel avenue for the
modulation of adult lung growth. Future studies in this area
will help to clarify the various cell signaling pathways that
play an essential role in the process of adult lung growth.
An important question is whether the results observed in
the immature recipients can be extrapolated to adults. We
now know that adult lung can be induced to grow by two
means, compensatory growth after lobectomy or pneu-
monectomy and transplantation into an immature recipient.
The ultimate goal of this research, in terms of clinical appli-
cation, is to be able to induce an adult lung to grow in a
rapid, healthy manner without surgery. To do this we must
discover the mechanisms that trigger and mediate adult lung
growth (either after lobectomy or after transplantation into
an immature recipient). This has potential therapeutic ben-
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efits for both adult and pediatric patients with lung disease
or lung injury.
We express our appreciation to Ms Kimberly Shockey, Mr
Anthony Herring, and Ms Sheila Hammond for their invaluable
technical assistance and to Dr Paul Davies for his assistance in
lung morphometric measurements.
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Discussion
Dr Michael J. Reardon (Houston, Tex). You studied the ipsi-
lateral lung in all these animals. Did you ever look at the con-
tralateral lung to see what was going on there?
Dr Kaza. No, we have not looked at the contralateral lung in
these experiments.
Dr Reardon. It would be interesting in your lung transplanta-
tion group to see what is happening in the contralateral lung.
Dr Frank W. Sellke (Boston, Mass). Why did you concentrate
on the EGF rather than several other growth factors?
Dr Kaza. We could have investigated various growth factors,
but our laboratory has been looking at EGFR expression because
we believe that EGF is one of the growth factors that is central to
this whole process of pulmonary morphogenesis. We are in the
process of doing gene array to look at a wide variety of genes and
their receptors to see whether they are upwardly regulated. We
chose to investigate the expression of EGFR for these particular
experiments, but we are going to investigate other growth factors
in the future.
Dr Sellke. Do you have any idea as to what is the inciting
influence that causes the increased expression of the growth fac-
tor?
Dr Kaza. We believe that it is a humoral response in relation
to a transient hypoxia that occurs after both lobectomy and trans-
plantation. When you remove the lobe or lung, the transient
hypoxia results in a humoral response that upwardly regulates
EGFR expression.
Sir Magdi Yacoub (Middlesex, United Kingdom). Have you
looked at the expression of retinoic acid receptor, because that has
been implicated in alveolar lung growth?
Dr Kaza. We have not looked at the retinoic acid receptor in
these experiments. However, we have recently published data
showing that retinoic acid does enhance compensatory lung
growth through the upward regulation of EGFR (Kaza AK, Kron
IL, Kern JA, Long SM, Fiser SM, Nguyen RP, Tribble CG, et al.
Retinoic acid enhances lung growth after pneumonectomy. Ann
Thorac Surg. 2001;71:1645-50).
Dr Raphael Bueno (Boston, Mass). Do you have any thoughts
as to which cells are proliferating and in the posttransplantation
situation; that is, whether they are the donor or the recipient cells?
Dr Kaza. With our immunohistochemical techniques we stain
all the cells that are in the lung, but when we analyze the CPI we
try to limit our count to the pneumocytes that are proliferating in
the transplanted lung. Because we limit our analyses to the trans-
planted lung, we can say that this response is being measured in
the donor cells.
